Manas AI Launches With $24.6M to Tackle Cancer Through AI-Driven Drug Discovery

Manas AI Launches With $24.6M to Tackle Cancer Through AI-Driven Drug Discovery

LinkedIn co-founder Reid Hoffman and renowned cancer researcher Siddhartha Mukherjee have co-founded Manas AI, a new startup leveraging artificial intelligence for drug discovery. The company has raised a $24.6 million seed round, co-led by General Catalyst and Hoffman, with participation from Greylock.  The startup will develop treatments initially targeting breast cancer, prostate cancer, and lymphoma.

Key Points:

  • Company brings together team of distinguished scientists, including five National Academy of Sciences members and two Breakthrough Prize recipients
  • Partnership with Microsoft enables molecular docking speeds 100 times faster than traditional systems
  • Platform combines generative computational chemistry with advanced molecular docking and wet lab validation

The launch of Manas AI, whose name derives from the Sanskrit word for "mind," comes at a time when AI drug discovery is attracting significant investment. The sector saw funding surge to $3.34 billion in 2024, representing a fivefold increase from the previous year, according to PitchBook data.

Mukherjee, a Columbia professor and Pulitzer Prize-winning author of "The Emperor of All Maladies," brings deep oncology expertise to the venture. The startup also boasts a roster of top-tier scientists known for breakthroughs in oncology, biochemistry, and computational chemistry. Among them are Dr. Lew Cantley, renowned for discovering important cancer-related enzymes; Dr. Gary Gilliland, whose genetics research shaped oncology treatments; and Dr. Craig Mello, a Nobel Laureate in Medicine.

The startup's approach centers on what it calls Project Cosmos, an ambitious AI initiative to map the fundamental rules of drug binding. This technical foundation is complemented by proprietary AI filters and chemical libraries designed to identify promising therapeutic candidates more rapidly than conventional methods.

The company's approach combines AI-driven molecule design with wet lab testing, distinguishing it from purely computational approaches. This hybrid methodology aims to address the challenges that have historically complicated AI drug discovery efforts, as biological systems have proven resistant to purely algorithmic solutions.

While Manas AI's seed funding appears modest compared to competitors like Xaira, which launched with $1 billion, or Treeline Biosciences' $422 million raise, the company's leadership brings unique advantages. Hoffman's tech industry connections, evidenced by the Microsoft partnership, could prove valuable as the company scales its computational capabilities.

The venture enters a competitive landscape where success remains elusive – no AI-discovered drugs have yet received regulatory approval. However, progress appears on the horizon, with Google DeepMind's CEO recently announcing plans to begin clinical trials for AI-designed drugs by year's end.

Chris McKay is the founder and chief editor of Maginative. His thought leadership in AI literacy and strategic AI adoption has been recognized by top academic institutions, media, and global brands.

Let’s stay in touch. Get the latest AI news from Maginative in your inbox.

Subscribe